Additional information
by Brett J. Skinner (Author)
What if Canada's pharmaceutical policies are doing more harm than good-sacrificing patient access and innovation in the name of cost control? In Building Better Pharma Policy in Canada, Brett J Skinner, PhD, delivers a compelling critique of how current government policies restrict access to new medicines, discourage investment, and erode the commercial value of pharmaceutical patents. Drawing on over a decade of in-depth research and data analysis, Skinner challenges common misconceptions about drug pricing, industry profits, and public drug plans.
The book presents a data-driven investigation into the unintended consequences of price regulation, delayed public drug coverage, and excessive bureaucracy. It reveals how Canada lags other nations on drug availability and efficiency while spending on patented medicines remains a fraction of total health expenditures. Skinner's analysis is rooted in economic principles and guided by concern for patient welfare and public accountability. He proposes actionable policy reforms to improve access, strengthen private-public insurance models, align with international best practices, and restore incentives for innovation.
Building Better Pharma Policy in Canada is a vital read for policymakers, healthcare professionals, industry leaders, and informed citizens who want to rethink how Canada approaches the economics of medicine-and how to ensure a better future for patients.
